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Background: Epidemiological studies have investigated the association between matrix metalloproteinase-3(MMP-3)
gene-1171 5A/6A polymorphism and rheumatoid arthritis (RA), but the results were inconsistent. To evaluate the
specific relationship, we performed a meta-analysis to clarify the controversies.
Methods: The relevant literatures dated to December 07th 2013 were retrieved from PubMed, EMBASE and the
China National knowledge Infrastructure (CNKI) databases. The number of the alleles and genotypes for MMP-3 were
obtained. Odds ratios (ORs) and 95% confidence intervals (CIs) were used to estimate the association between
MMP-3 5A/6A promoter polymorphism and RA. All of the statistical analyses were conducted by STATA11.0 software.
Results: A total of 6 case-control studies covering 1451 cases and 1239 controls were included in the final
meta-analysis. There was no significant association between MMP-3 5A/6A promoter polymorphism and RA in
all genetic models (for 6A versus 5A: OR = 1.19, 95% CI = 0.91-1.56, P = 0.203; 5A/6A versus 5A/5A: OR = 1.31, 95%
CI = 0.89-1.92, P = 0.174; 6A/6A versus 5A/5A: OR = 1.78, 95% CI = 0.68-4.61, P = 0.238; the recessive model: OR = 1.48,
95% CI = 0.88-2.47, P = 0.141; and the dominant model: OR = 1.46, 95% CI = 0.71-3.00, P = 0.299). In the subgroup
analysis by ethnicity, we obtained the similar results.
Conclusions: We systematically investigate the association between MMP-3-1171 5A/6A polymorphism and RA
susceptibility; however, the results show a lack of correlation. Considering the small sample size and the selection
bias existed in some studies, further studies are needed to confirm the findings.
Keywords: Rheumatoid arthritis, Matrix metalloproteinase, Polymorphism, Susceptibility, Meta-analysisBackground
Rheumatoid arthritis (RA) is an autoimmune inflammatory
disease and the etiology is still unknown. It is characterized
by synovial inflammation and hyperplasia, autoantibody
production, cartilage and bone destruction [1,2]. The envir-
onment factor and genetic participate in mechanisms of
RA [3,4]. Recently, research has focused on the identifi-
cation of genes that influence the susceptibility of this
disorder. Therefore, analysis and identification of new
genes associated with RA susceptibility is an important
and meaningful challenge.* Correspondence: szwzz001@163.com; lj40038@126.com
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unless otherwise stated.The clinical manifestations and outcomes of RA range
from mild to severe polyarthritis with progressive destruc-
tion of cartilage and bone. Much of the destruction in
RA is mediated by abnormal release of matrix metallo-
proteinase (MMPs) in synovium stimulated by persistent
inflammation [5]. MMPs are a group of zinc-dependent
endopeptidases, which can degrade every component of
the extracellular matrix. In the synovial joint, MMPs are
mainly secreted by fibroblasts, macrophages and chon-
drocytes. The expression of most MMPs is regulated at
the transcription level by growth factors, hormones,
and cytokines [6].
MMP-3(stromelysin 1) is considered to be the main
MMP involved in cartilage degradation and the most
widely studied member in RA. It has broader substrate
specificity with activity against type II, III, IV, IX, X, XId. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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addition, it can activate other MMPs such as MMP-1,-2,
-9 and -13 [6,7]. It has been reported that the serum and
synovial fluid levels of MMP-3 are elevated in early and
established RA patients, and are associated with diseased
activity and /or joint destruction [8-11].
In recent years, a single nucleotide polymorphism (SNP)
in the promoter sequence of the MMP-3 gene have been
described [12-14], and this polymorphism may play an
important role in regulating the MMP-3 gene expression
[15]. In human, the MMP-3 gene is located at the long
arm of chromosome 11 (11q22.3) [16], and the promoter
region of MMP-3 is characterized by 5A/6A promoter
polymorphism at position of -1171(rs3025082), in which
one allele has six adenosines(6A) and the second has five
adenosines(5A) [12], while the 6A allele has about half the
promoter strength of the 5A allele [15].
The association between MMP-3 gene polymorphism
and RA susceptibility has been investigated, but the results
between studies are either inconsistent or lack strength
owing to small sample sizes. Therefore, the purpose of
this study was to ascertain whether polymorphism in




This meta-analysis followed the preferred reporting items
for Meta-analysis Of Observational Studies in Epidemiology
(MOOSE) group [17]. The PubMed, Embase and Chinese
National Knowledge Infrastructure (CNKI) databases were
searched (updated to Dec 07th, 2013) with terms ‘Matrix
Metalloproteinase 3’, ‘stromelysin 1’, ‘MMP-3’, ‘rs3025058’,
‘polymorphism’, ‘Genome-Wide Association Study’, ‘arthritis,
rheumatoid’ and ‘RA’, as both medical subject heading
(MeSH) terms and text words to find all papers that had
studied the association of MMP-3 5A/6A SNP with RA.
Manual search of references from original research or
review articles was performed to identify additional stud-
ies. No language and time restrictions were applied.
Inclusion criteria
Studies were included if they complied with all the follow-
ing criteria: (a) case-control study on the association of
MMP-3 5A/6A promoter polymorphism with RA; (b) suffi-
cient published data for estimating the odds ratio (OR) with
95% confidence interval (CI); (c) For multiple publications
reporting on the same data or overlapping data, the largest
or most recent publication was selected [18].
Exclusion criteria
Studies were excluded if: (a) containing overlapping data;
(b) genotype distribution of the control population is not
in Hardy–Weinberg equilibrium (HWE); and (c) studiesin which family members had been studied because their
analysis is based on linkage considerations.
Data extraction
Study selection was carried out independently by two
investigators (Feng and He) according to the inclusion and
exclusion criteria listed above. The following data were
extracted from eligible studies: the first author's name,
year of publication, country of origin, ethnicity of the
studied population, total numbers of cases and controls,
numbers of cases and controls with different genotypes
respectively. Furthermore, evidence of Hardy-Weinberg
equilibrium (HWE) was collected. Data were extracted
independently by two investigators (Feng and He), and
consensuses were reached on all items. A third investi-
gator (Juan Li) was to adjudicate any disagreement if
consensus could not be reached.
Quality score assessment
The quality of included studies was evaluated independ-
ently by two authors (Feng and He) of this article according
to the Newcastle–Ottawa Scale (NOS) for case-control
studies [19]. The NOS ranges between zero (worst) and
nine stars (best). Disagreement was resolved by discussion.
A third investigator (Juan Li) was to adjudicate any dis-
agreement if it was necessary.
Statistical methods
Fisher's exact test was used to assess deviation from HWE
in the control group according to genotypes. Crude OR
with their 95% CI was estimated and used to assess the
strength of association between MMP-3 5A/6A promoter
polymorphism and RA. The pooled OR was calculated
respectively for allelic effect of 6A versus 5A, homozygote
comparison of 6A/6A versus 5A/5A, recessive model (6A/
6A versus 5A/5A +5A/6A) and dominant model (6A/
6A +5A/6A versus 5A/5A). The significance of the
pooled OR was determined by the Z-test. (P ≤0.05 was
considered representative of statistical significance).
Heterogeneity among studies was examined using
Cochran's Q statistic and the I2 statistic (P <0.10 and I2 >
50% indicated the evidence of heterogeneity) [20]. If there
was no statistical heterogeneity among studies, the fixed-
effect model was used; otherwise the random-effect model
was used [21]. Subgroup analysis was performed by ethni-
city. Sensitivity analysis was determined by deleting each
single study in each meta-analysis to reflect the influence
of the individual data-set to the pooled OR. An estimate
of potential publication bias was carried out by Begg's
funnel plot and Egger's regression test [22]. All of the
statistical analyses were conducted by STATA11.0
software (Stata Corporation, College Station, TX, USA).
(P ≤0.05 was considered significant). Our study followed
the PRISMA guidelines (Additional file 1).
Feng et al. BMC Musculoskeletal Disorders 2014, 15:376 Page 3 of 8
http://www.biomedcentral.com/1471-2474/15/376Results
Characteristics of included studies
The study selection process is detailed in Figure 1. Based
on our search strategy, 83 relevant studies were achieved
by identification through systematic searches and a review
of references. 28 eligible studies were retrieved for detailed
evaluation. During the procedure of data extraction, 14
articles were excluded because they were not focused on
RA or rs3025058. In addition, 8 records were because they
did not have control groups. Finally, a total of 6 case-
control studies including 1451 cases and 1239 controls in
6 articles met our inclusion criteria reported the associ-
ation between MMP-3 5A/6A promoter polymorphism
and RA [23-28]. The characteristics of selected studies
were summarized in Table 1. Of the ethnicity among all
studies, there were five in Caucasian [23-25,27,28] and
one in Asian [26]. The distribution of genotypes did not
deviate from HWE in the controls group of all included
studies. The NOS results showed that the average score
was 7.67, which indicated that the methodological quality
was generally good.
Quantitative synthesis
The association between MMP-3 5A/6A promoter poly-
morphism and RA was investigated in six studies with a
total of 1451 RA cases and 1239 controls. Given that
significance between-study heterogeneity existed in overall
comparisons except 5A/6A versus 5A/5A (for 6A versus
5A: I2 = 76.4%, Ph = 0.001; 5A/6A versus 5A/5A: I
2 = 50.9%,
Ph = 0.106; 6A/6A versus 5A/5A: I
2 = 78.6%, Ph = 0.003; theFigure 1 Flow diagram of selected of studies and specific reasons
for exclusion from the meta-analysis.recessive model: I2 = 68.6%, Ph = 0.023; and the dominant
model: I2 = 71.3%, Ph = 0.015), we used fixed-effect model
for comparison 5A/6A versus 5A/5A and used the
random-effect model for others. Overall, there was no
significant association between MMP-3 5A/6A promoter
polymorphism and RA (for 6A versus 5A: OR = 1.19, 95%
CI = 0.91-1.56, P = 0.203; 5A/6A versus 5A/5A: OR = 1.31,
95% CI = 0.89-1.92, P = 0.174; 6A/6A versus 5A/5A: OR =
1.78, 95% CI = 0.68-4.61, P = 0.238; the recessive model:
OR = 1.48, 95% CI = 0.88-2.47, P = 0.141; and the domin-
ant model: OR = 1.46, 95% CI = 0.71-3.00, P = 0.299). The
main results of meta-analysis were shown in Table 2.
In the subgroup analysis by ethnicity, we only analyzed
the Caucasians as just one study involved in Asians pop-
ulations. We obtained similar results that no significant
association was found in all genetic models. The results
of subgroup analysis quantitatively illustrated that MMP-3
5A/6A promoter polymorphism did not associate with
RA. The main results of subgroup analysis were shown in
Table 2.
Sensitivity analysis and Publication bias
Sensitivity analyses were preformed to assess the stability
of the results. The result did not change when a single
study involved in the meta-analysis was deleted each time.
The shapes of the Begg's funnel plots did not reveal any
evidence of obvious asymmetry in all genetic models
(Figure 2). Meanwhile, the results of Egger's regression
test still did not provide any evidence of publication bias
(P = 0.461 for 6A versus 5A, P = 0.824 for 5A/6A versus
5A/5A, P = 0.835 for 6A/6A versus 5A/5A, P = 0.257 for
recessive model and P = 0.766 for dominant model,
respectively) (Table 2).
Discussion
RA is characterized by chronic inflammation of synovial
tissue and progressive destruction of cartilage and bone.
Progressive joint destruction is one of the strongest pre-
dictors of long-term outcome and disability in RA [29].
Synoviocytes produce a wide range of proinflammatory
cytokines such as interleukin 1(IL-1), IL-6 and tumour
necrosis factor (TNF) which stimulate osteoclast like
cells to secrete proteolytic enzymes such as MMPs. IL-1
stimulates synoviocytes and chondrocytes to release MMPs
such as MMP-3 that degrade collagen, resulting in extra-
cellular matrix degradation ultimately leading to cartilage
and bone loss [30,31].
MMP-3 is believed to play a pivotal role involving in
joint destruction in RA, and there is a common poly-
morphism in the promoter sequence of the MMP-3 gene
[12,13], which may be correlated with RA susceptibility.
Although large-scale genome wide association studies
(GWAS) reveal a number of SNP markers that reprodu-
cibly associate with RA susceptibility [3], substantially
Table 1 Characteristics of studies included in this meta-analysis
Author year Ethnicity HWE (P) Score Sample size
(case/control)
Case (%) Control (%)
5A 6A 6A/6A 5A/6A 5A/5A 5A 6A 6A/6A 5A/6A 5A/5A
Abd-Allah 2012 Caucasian (Egypt) Y (0.986) 8 100/100 88 (44.0) 112 (56.0) 33 (33.0) 46 (46.0) 21 (21.0) 128 (64.0) 72 (36.0) 13 (13.0) 46 (46.0) 41 (41.0)
Constantin 2002 Caucasian (France) Y (0.213) 8 102/126 98 (48.0) 106 (52.0) 27 (26.5) 52 (51.0) 23 (22.5) 111 (44.0) 141 (56.0) 36 (28.5) 69 (54.8) 21 (16.7)
Dörr 2004 Caucasian (Germany) Y* 8 308/110 306 (49.6) 310 (50.4) NM NM NM 103 (46.8) 117 (53.2) NM NM NM
Rodrigue 2006 Caucasian (Spain) Y* 7 550/652 556 (50.5) 544 (49.5) NM NM NM 674 (51.7) 630 (48.3) NM NM NM
Scherer 2010 Caucasian (Brazil) Y (0.130) 8 110/100 71 (32.3) 149 (67.7) 52 (47.3) 45 (40.9) 13 (11.8) 90 (45.0) 110 (55.0) 34 (34.0) 42 (42.0) 24 (24.0)
Zhou 2007 Asian (China) Y (0.150) 7 281/151 65 (11.6) 497 (88.4) 224 (79.7) 49 (17.4) 8 (2.8) 36 (11.9) 266 (88.1) 119 (78.8) 28 (18.5) 4 (2.7)























Sample size (case/control) OR (95% CI) Ph P Pr Sample size (case/control) OR (95% CI) Ph P
6A vs 5A 2902/2478 1.19(0.91-1.56)* 0.001 0.203 0.461 2340/2176 1.23(0.89-1.68)* 0.000 0.207
5A/6A vs 5A/5A 257/275 1.31(0.89-1.92) 0.106 0.174 0.824 200/243 1.37(0.68-2.76)* 0.058 0.373
6A/6A vs 5A/5A 401/292 1.78(0.68-4.61)* 0.003 0.238 0.835 169/169 2.11(0.66-6.67)* 0.002 0.209
Dominant model 593/477 1.46(0.71-3.00)* 0.015 0.299 0.766 312/326 1.61(0.68-3.80)* 0.008 0.274
Recessive model 593/477 1.48(0.88-2.47)* 0.023 0.141 0.257 312/326 1.69(0.84-3.40)* 0.021 0.142
Dominant model: 6A/6A +5A/6A versus 5A/5A, Recessive model: 6A/6A versus 5A/5A +5A/6A, OR: odds ratio, CI: confidence interval, Ph: P -value of Q-test for
heterogeneity test, P: P -value of Z-test for significance of the pooled OR, Pr: P -value of Egger's regression test for publication bias, *Significant heterogeneity:
the random-effect model was chosen to summarize the result.
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of disease susceptibility, however, hundreds of common
risk alleles are likely to exist but remain undiscovered to
date owing to the limited power of current GWAS [4].
And the association between MMP-3 gene polymorphism
and RA was poorly understood.
Currently, more and more evidences showed that 5A/
6A polymorphisms in the MMP-3 gene promoter were
presumably associated with susceptibility and severity
of RA. Constantin et al. found that the MMP-3 6A/6A
genotype was associated with the highest total radio-
graphic damage score (TDS) both at baseline and after
a 4-year follow-up and with the highest progression of
the TDS over the 4 years of follow-up in patients with
early RA, but not RA susceptibility. And they also showed
the serum concentration of MMP-3 did not differ between
the three MMP-3 genotypes [23]. Likewise, Mattey et al.
showed established RA patients homozygous for the
MMP-3 6A allele had more radiographic damage than
those with other genotypes, but that patients with the
6A/6A genotype also had more functional impairment
and higher serum proMMP-3 levels [32]. In Japanese
patients Tsukahara et al. found the effect of the 6A
allele on increasing level of serum MMP-3, no significant
effect of the polymorphism was found on the disease
activity or severity of RA, though a trend of an effect of
5A allele on the Sharp/van der Heijde score was observed
[33]. Interestingly, Scherer et al. observed that the 6A
allele was associated with higher RA susceptibility, but
RA patients homozygous for 6A allele have significant
lower frequency of extra-articular manifestation and of
rheumatoid nodules than patients carrying 5A allele
[27]. In the study of Abd-Allah et al. also found that
there were significant associations between MMP-3
(-1171 5A/6A) polymorphism and susceptibility to RA.
The 6A/6A genotype and 6A allele were significantly
more frequent in the patients with RA and than in the
control group. There was also an association between
MMP-3 5A/6A polymorphism and the severity in RA
patients. But, they found that there were no significant
association between the MMP-3 levels and the allelicvariants of MMP-3 polymorphism [28]. Meanwhile,
Nemec et al. revealed RA patients with 5A allele presented
more progressive radiographic joints damage, but with the
6A/6A genotype had lower risk to develop erosive RA [34].
Ye et al. reported that RA patients with the MMP-3 5A/5A
genotype were also associated with higher Steinbrocker
index and health assessment questionnaire [35]. However,
the results from Rodriguez-Lopez et al. showed that 5A
allele frequency did not disclose significant differences
between RA patients and controls [25]. Even more peculiar,
Dörr et al. found no association between MMP-3 poly-
morphism and the susceptibility or radiographic damage,
and the plasma concentrations of MMP-3 were not sig-
nificantly different between patients groups with
defined MMP alleles [24].
From the above it can be seen that the conflict results
and small sample size are too underpowered to detect a
possible effect of the MMP-3 gene polymorphism on RA.
Thus, we conducted this meta-analysis to better understand
the association between MMP-3 gene polymorphism and
susceptibility of RA.
To the best of our knowledge, this is the first meta-
analysis to investigate the association of MMP-3 gene
polymorphism with RA, and the influence of this gene
polymorphism on RA susceptibility in different ethnic
populations. In this meta-analysis, a total 1451 RA pa-
tients and 1239 controls were analyzed to provide overall
assessment of the association between MMP-3 5A/6A
polymorphism and RA susceptibility. The results mani-
fested that there was no association between MMP-3 5A/
6A polymorphism and RA susceptibility. Neither allele
frequency nor genotype distribution was significantly as-
sociated with susceptibility to RA. Considering the ethnic
may influence the consequences, subgroup analyses were
performed to further investigate the potential association.
However, the similar results were observed in Caucasians.
It is not surprising that our study failed to detect any
connection of the MMP-3 polymorphism with the
susceptibility to RA. There are several reasons for this
phenomenon, first of all, RA is a complex disease
and multiple genes, different genetic backgrounds, and
Figure 2 Funnel plots of the association between MMP-3-1171 5A/6A polymorphism and RA. A (alleles model: 6A vs 5A), B (alleles model:5A/
6A vs 5A/5A), C (alleles model: 6A/6A vs 5A/5A), D (Recessive model: 6A/6A versus 5A/5A +5A/6A) and E (Dominant model: 6A/6A +5A/6A vs 5A/5A).
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RA. Secondly, the MMP-3 5A/6A polymorphism is in
linkage disequilibrium with MMP-1 1G/2G which is
linked to RA [24]. Thirdly, some other as-yet unidentified
genes might conceal the influence of the alleles. Therefore,
our findings suggest that further investigations are re-
quired before we are able to determine the association be-
tween the MMP-3 5A/6A polymorphism and RA.Moreover, the present study has some limitation should
be discussed. First, significance between-study heterogen-
eity was observed in most comparisons. It may affect
the precision of results although we use random-effect
model to pool ORs. The heterogeneity may attribute to
the confounding factors due to case definition, sample
size and methods of genotyping. Although we conducted
sensitivity analysis, the heterogeneity was still observed.
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and Asian, thus our study should be optimized by larger
scale of populations. Third, lack of the original data of
available studies limited our further evaluation of potential
interactions, such as age, gender, environmental factors.
Forth, due to different assessment methods of joints de-
struction, we did not investigate the association between
MMP-3 gene polymorphism and RA severity. Finally,
some inevitable publication bias may exist in the results,
although neither the Begg's funnel plots nor Egger's re-
gression test indicated obvious publication bias in our
meta-analysis.
Conclusions
Our meta-analysis demonstrate that a lack of MMP-3
gene polymorphism with susceptibility to RA. Neverthe-
less, increasing evidences manifest that this polymorphism
may correlate with severity of RA. Thus, further studies
in large cohorts of RA and in different populations are
necessary to elucidate the association between MMP-3
-1171 5A/6A polymorphism and RA.
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